Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | PPIA | P62937 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | PPIF | P30405 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | KDM1A | O60341 | 2/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10490780 | 0.94 | KMT2A (0.59) | POLBPPIAMEN1KMT2ANPC1 | |
| SCHEMBL3048489 | 0.89 | ALDH1A1 (0.57) | PPIAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL10639177 | 0.88 | MEN1 (0.63) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL28915066 | 0.86 | MEN1 (0.68) | POLBPPIAMEN1KMT2ANPC1 | |
| SCHEMBL94347 | 0.86 | ALDH1A1 (0.55) | PPIAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL28362194 | 0.86 | POLB (0.62) | POLBPPIAMEN1KMT2ANPC1 | |
| SCHEMBL5675541 | 0.85 | ALDH1A1 (0.57) | PPIAMEN1KMT2AMAPTPPIF | |
| SCHEMBL13915753 | 0.85 | ALDH1A1 (0.67) | POLBPPIAMEN1KMT2ANPC1 | |
| SCHEMBL8867503 | 0.85 | ALDH1A1 (0.54) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL8867506 | 0.85 | TSHR (0.60) | MEN1KMT2ANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115477634-B | Analgesic compounds and medical uses thereof | 中国人民解放军军事科学院军事医学研究院 | 2024-02-13 | — | — | CN | disclosed |
| CN-115477634-A | Compound for analgesia and medical application thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022253035-A1 | ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| CN-112159401-A | Biased agonist and medical application thereof | 中国人民解放军军事科学院军事医学研究院 | 2021-01-01 | — | — | CN | disclosed |
| US-20170246627-A1 | DIAGNOSTIC DEVICES WITH MODIFIABLE HYDROPHOBIC SURFACES | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246627-A1 | DIAGNOSTIC DEVICES WITH MODIFIABLE HYDROPHOBIC SURFACES | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2017-08-31 | — | — | US | disclosed |
| WO-2016036658-A1 | DIAGNOSTIC DEVICES WITH MODIFIABLE HYDROPHOBIC SURFACES | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| EP-1526132-B1 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-8129378-B2 | Rivaroxaban and derivatives, synthesis; atherosclerosis; arthritis; Alzheimer's disease or cancer | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20100267685-A1 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | BAYER HEALTHCARE AG | 2008-12-11 | — | — | US | disclosed |
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008052671-A2 | COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | WO | disclosed |
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| WO-2007039134-A1 | COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-7157456-B2 | Anticoagulates for treating cardiovascular disorders, such as myocardial infarct, angina pectoris, restenoses after angioplasty, bypass, stroke; treatment of atherosclerosis, arthritis, Alzheimer's disease or cancer | BAYER HEALTHCARE AG (DE) | 2007-01-02 | — | — | US | disclosed |
| WO-2003000256-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
| US-5190862-A | Peptide modified compound | BOEHRINGER MANNHEIM GMBH (DE) | 1993-03-02 | — | — | US | disclosed |
| US-5108890-A | Diagnostic agents for determining peptide bond-cleaving enzymes; measuring light absorbed by liberated colored materials | BOEHRINGER MANNHEIM GMBH (DE) | 1992-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | POLB 1473/4885PPIA 391/4885MEN1 2299/4885 |
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | OTC, SDHA, SDHB | POLB 1709/4885PPIA 531/4885MEN1 1665/4885 |
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | POLB 1473/4885PPIA 391/4885MEN1 2299/4885 |
| US-20100267685-A1 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones | SERPINC1, SDHB, F2 | POLB 697/4885PPIA 176/4885MEN1 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.